

FLEVOX[®] THE NEW PARASITICIDE FOR DOGS AND CATS

Lure (France), 14 February 2012 - Vétoquinol launches Flevox[®], the latest addition to its range of parasiticides. The new drug is based on fipronil, the molecule par excellence in the treatment of tick and flea infestations in pets.



Flevox® marks the completion of the Group's range of parasiticides for pets. It combines the advantages of efficacy and simple administration for pet owners. The range also includes Dolpac®, an internal parasiticide. Flevox® will be marketed in 5 different dosages and 2 different pack sizes, giving veterinarians greater flexibility when delivering the drug.

The parasiticide market is a major segment of the animal health market, accounting for nearly 20% of the world market. The European market is estimated at around $\in\!800$ million. The launch of $\mathsf{Flevox}^{\$}$ in Europe positions Vétoquinol in a large and dynamic segment of the market.

"With Flevox® we are now able to offer a comprehensive range of internal and external parasiticides", Vétoquinol CEO Matthieu Frechin explained. "As usual with Vétoquinol, our competitive edge will hinge on the customer service we provide to veterinarians. We expect the European market to give the product a hearty welcome, given that spring is normally the season for starting parasite treatment".



About Vétoquinol

Vétoquinol is an independent veterinary pharmaceutical laboratory serving both the companion and production animal markets. This family-owned group, dedicated exclusively to animal health, is the $10^{\rm th}$ largest animal healthcare laboratory in the world. More than 80% of its revenues are generated outside France.

Vétoquinol's business includes research and development, production and marketing of medicinal and non-medicinal products. Vétoquinol has positioned itself in the curative sector and has developed expertise in three therapeutic fields: anti-infectives, pain/inflammation and cardiology/nephrology. The Group currently distributes its products in more than one hundred countries throughout Europe, North America and Asia/Pacific, with subsidiaries in 23 countries and a network of 140 distribution partners. The company has 1,750 employees worldwide.

For more information: www.vetoguinol.com.

OUR BUSINESS: ANIMALS. OUR ADVANTAGE: PEOPLE.

For more information, contact:

VETOQUINOL<u>Finance department</u>
Marie-Josée AUBRY-ROTA
Tel.: 03 84 62 59 88

relations.investisseurs@vetoquinol.com

KEIMA COMMUNICATION

Investor relations
Emmanuel DOVERGNE
Tel.: 01 56 43 44 63
emmanuel.dovergne@keima.fr

Media relations
Alix HERIARD DUBREUIL
Tel.: 01 56 43 44 62
alix.heriard@keima.fr